Compare Alcon AG (ALC) vs Enbridge Inc (ENB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Enbridge Inc — how do they compare? Alcon AG trades at $66.89 (market cap $32.69B), while Enbridge Inc trades at $55.05 (market cap $120.14B). The key difference: Enbridge Inc is far larger — about 3.7× Alcon AG's market cap, and Enbridge Inc pays the higher dividend (5.11%). Which is the better fit depends on your goals.
| ALC | ENB | |
|---|---|---|
Market Cap | $32.69B | $120.14B |
Sector | Health | Energy |
52-Week High | $92.22 | $58.04 |
52-Week Low | $62.02 | $43.79 |
Enterprise Value | $36.28B | $200.94B |
Dividend Yield | 0.54% | 5.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Enbridge (ENB) trades at $55.05, up 1.79% for the day, with a bearish technical signal from moving averages. The company reported strong revenue growth to $65.19B in 2025 and a net income margin of 10%, though it missed Q3 2025 EPS estimates. Recent news highlights include a dividend payment of $0.97 and upcoming Q2 2026 earnings on July 31, 2026. Analyst consensus is split evenly between Buy and Hold ratings.
Outlook remains mixed with solid cash flow from operations supporting dividends, but debt levels have risen to 48.81% of assets. Key risks include energy market volatility and execution of growth projects. The stock offers a high yield but faces near-term technical pressure and valuation concerns at a P/E of 25.73.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
